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57 ABSTRACT 
A non-human transgenic mammalian animal, as described 
above, contains an exogenous double Stranded DNA 
Sequence Stably integrated into the genome of the animal, 
which comprises cis-acting regulatory units operably linked 
to a DNA sequence encoding human Factor VIII protein and 
a signal peptide, where the cis-acting regulatory units are 
active in mammary gland cells and the Signal peptide is 
active in directing newly expressed Factor VIII into the milk 
of the animal. The promoter may be a milk protein promoter 
Such as for whey acidic protein, casein, lactalbumin, or 
beta-lactoglobulin promoter. The transgenic mammals are 
preferably farm animals, for example, cows, goats, sheep, 
rabbits and pigs. Concurrent expression of a gene for human 
von Willebrand's Factor into milk may be used to stabilize 
newly-secreted Factor VIII. 
42 Claims, 3 Drawing Sheets 
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TRANSGENIC MAMMALS EXPRESSING 
HUMAN COAGULATION FACTOR VIII 
BACKGROUND OF THE INVENTION 
This invention relates generally to transgenic animals and 
their use as bioreactors for the production of clinically useful 
quantities of proteins. More Specifically, this invention 
relates to a non-human transgenic animal genetically engi 
neered to express recombinant human Factor VIII protein or 
von Willebrand Factor protein and to secrete newly 
expressed protein into a body fluid from which the protein 
can readily be isolated. 
Factor VIII (“F8”) is a blood plasma glycoprotein of about 
260 kDa molecular mass produced in the liver of mammals. 
It is a critical component of the cascade of coagulation 
reactions that lead to blood clotting. Within this cascade is 
a step in which Factor IXa, in conjunction with F8, converts 
Factor X to an activated form, Factor Xa. F8 acts as a 
cofactor at this step, being required with calcium ions and 
phospholipid for the activity of Factor IXa. The two most 
common hemophilic disorders are caused by a deficiency of 
functional F8 (Hemophilia A, about 80% of all cases) or 
functional Factor IXa (Hemophilia B or Christmas Factor 
disease). 
Until recently, the standard treatment of Hemophilia A 
involved frequent infusions of preparations of F8 concen 
trates derived from the plasmas of human donors. While this 
replacement therapy is generally effective, Such treatment 
puts patients at risk for virus-transmissible diseaseS Such as 
hepatitis and AIDS. Although this risk has been reduced by 
further purification of F8 from plasma by immunopurifica 
tion using monoclonal antibodies, and by inactivating 
Viruses by treatment with either an organic Solvent or heat, 
Such preparations have greatly increased the cost of 
treatment, and are not without risk. For these reasons, 
patients have been treated episodically, rather than prophy 
lactically. A further complication is that about 15% of 
patients develop inhibitory antibodies to thus-prepared F8. 
An important advance in the treatment of Hemophilia A 
has been the isolation of cDNA clones encoding the com 
plete 2,351 amino acid sequence of human F8 (see, Wood et 
al, Nature, 312:330 (1984) and U.S. Pat. No. 4,757,006, Jul. 
12, 1988) and the provision of the human F8 gene DNA 
Sequence and recombinant methods for its production). 
Analysis of the deduced primary amino acid Sequence of 
human F8 determined from the cloned cDNA indicates that 
it is a heterodimer processed from a larger precursor 
polypeptide. The heterodimer consists of a C-terminal light 
chain of about 80 kDa in a metal ion-dependent association 
with an about 210 kDa N-terminal heavy chain fragment. 
See review by Kaufman, Transfusion Med. Rev.S., 6: 235 
(1992). Physiological activation of the heterodimer occurs 
through proteolytic cleavage of the protein chains by throm 
bin (Factor IIa). Thrombin cleaves the heavy chain to a 90 
kDa protein, and thence to 54 kDa and 44 kDa fragments. 
Thrombin also cleaves the 80 kDa light chain to a 72 kDa 
protein. It is the latter protein, and the two heavy chain 
fragments (54 kDa and 44 kDa above), held together by 
calcium ions, that constitute active F8. Inactivation occurs 
when the 72 kDa and 54 kDa proteins are further cleaved by 
thrombin, activated protein C or Factor Xa. In plasma, this 
F8 complex is stabilized by association with a 50-fold 
excess of von Willebrand Factor protein (“vWF"), which 
appears to inhibit proteolytic destruction of F8. 
The amino acid Sequence of F8 is organized into three 












acids, a Single B domain of 980 amino acids, and a dupli 
cated C domain of 150 amino acids. The B domain has no 
homology to other proteins and provides 18 of the 25 
potential asparagine(N)-linked glycosylation sites of this 
protein. Although porcine and human F8 show Striking 
divergence in their B domains, the porcine protein can be 
used to treat Hemophilia A in humans. This Suggests either 
that the B chain is not critical to the biological activity of the 
holomolecule, or that multiple versions of this domain are 
similarly effective. Porcine and human F8 show 80-85% 
homology in two of the three A domains. 
Although the hepatocyte is likely to be the cell type that 
produces F8 in Vivo, to date there are no known natural cell 
lines that express this protein. Kaufman, 1992, above, and 
Wood et al. 1984, above transfected transformed hamster 
kidney cells with a vector containing a gene that encodes F8, 
and expressed this protein. Kaufman, Nature 342: 207 
(1989), expressed recombinant F8 in transformed CHO 
cells, but production and Secretion of newly Synthesized 
protein into the conditioned growth medium was very low. 
This was Said to have been due to three factors: a require 
ment for the presence of the VWF in the conditioned medium 
used in these culture Systems in order to protect newly 
secreted F8 from proteolytic destruction (in the absence of 
v WF, Factor VIII was secreted as incomplete chains that 
were Subsequently degraded); incomplete Secretion of newly 
synthesized F8 from the cells (most remained in the endo 
plasmic reticulum); and, a low level of F8 mRNA as a result 
of a post-translational event. Stable recombinant F8 was 
secreted by CHO cells only when the gene for VWF was 
concurrently expressed. Additional drawbacks to the use of 
mammalian tissue culture Systems for the production of F8 
in clinically useful quantities are the expense of growth 
media and the limited production capacity of mammalian 
tissue culture Systems. 
An important need remains for an efficient and relatively 
inexpensive means of producing large quantities of infec 
tious particle-free, human F8 protein Suitable for clinical 
use. The transgenic animal System described below that 
produces human F8 recombinantly Satisfies this need. 
It has been estimated, for example, by Paleyanda et al., in 
RECOMBINANT TECHNOLOGY IN HEMOSTASIS 
AND THROMBOSIS eds., Hoyer et al., (Plenum Press, 
N.Y. 1991), that the U.S. market for F8 is about 600,000,000 
units per year. At a specific activity of 5,000 U/mg, about 
120 g a year are required. ASSuming an achievable expres 
Sion level of 50 mg/L in the milk of a transgenic animal of 
the invention and a 50% loss of the protein during 
purification, it has been estimated that about 1 cow 
(producing 6,000 L of milk yearly), 10 goats, sheep or pigs 
(producing 500 L of milk yearly), or 5,333 rabbits 
(producing 0.9 L of milk yearly) would be more than 
sufficient to supply all of this country's needs for F8 
(Paleyanda et al., above). 
SUMMARY OF THE INVENTION 
It is therefore an object of this invention to provide a 
non-human, transgenic female mammalian animal that pro 
duces F8. 
It is another object of the invention to provide a process 
for producing transgenic mammals with the aforementioned 
characteristic. 
It is still another object of the invention to provide a 
method for producing F8 in commercially valuable amounts, 
by inducing a non-human transgenic female mammal to 
Secrete expressed F8 into its milk, and isolating this protein 
from the milk. 
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It is yet another object to provide a transgenic animal that 
has had stably integrated into its genome DNAS encoding 
both F8 and v WF, such that both proteins are expressed and 
Secreted into the animal's milk. 
These objects have been realized by the production of a 
non-human transgenic female mammalian animal into 
whose genome is stably integrated an exogenous recombi 
nant double Stranded DNA sequence comprising a protein 
promoter Specifically active in a Secretory gland operably 
linked to a DNA sequence encoding F8 or vWF or both 
proteins and a Signal peptide effective in directing Secretion 
of newly expressed F8 protein into a body fluid of the 
animal. More particularly, the protein promoter is for a milk 
protein and the Signal peptide directs the expressed F8 into 
the animal’s milk. 
These objects are also realized by the provision of double 
Stranded DNA constructs comprising a tissue-specific active 
protein promoter operably linked to a DNA sequence encod 
ing F8 or VWF and a DNA sequence encoding a signal 
peptide that directs newly expressed F8 or VWF into the host 
animal's body fluid, which constructs are used to produce 
the transgenic animal. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description and the appended claims. It should be 
understood, however, that the detailed description and 
examples given below, while indicating preferred 
embodiments, should not be considered limiting in any way 
as various changes and modifications within the Spirit and 
Scope of the invention will become apparent to the skilled 
artisan from this detailed description. 
DESCRIPTION OF THE FIGURES 
FIG. 1 is a schematic representation of a human F8 cDNA 
construct showing the contribution of whey acid protein 
(“WAP) genomic sequences. The 14.6 kb insert, composed 
of a 2.6 kb 5’ WAP gene, a 7.5 kb human F8 cDNA and a 4.6 
kb 3WAP gene, can be excised by Not I digestion of the 
plasmid, releasing the 2.1 kb pPoly III D vector. 
FIG. 2 is a Schematic representation of the production of 
a mouse WAP-Human F8 cDNA hybrid gene, showing the 
insertion of a 7.5 kb human F8 cDNA at the Kpn I site of the 
mouse WAP gene, in the p225.11 plasmid. 
FIG. 3 is a sketch showing a Western blot of separated 
milk whey proteins obtained from transgenic mice induced 
to express human F8 into their milk. The first lane on the left 
shows molecular weight markers. The next lane shows 
authentic human F8 with major bands at about 80 kDa and 
about 210 kDa. The next lane shows the proteins in control 
whey. Lanes marked F2 and F3 show the proteins in the 
whey of transgenic mice induced to express recombinant 
human F8. 
DETAILED DESCRIPTION OF THE 
INVENTION 
There has been invented a non-human transgenic female 
mammalian animal into whose genome is stably integrated 
an exogenous DNA sequence comprising a milk protein 
promoter Specifically active in mammary gland cells oper 
ably linked to a DNASequence encoding a human F8 protein 
and a signal Sequence effective in directing Secretion of 
newly expressed F8 protein into the milk of the transgenic 
animal. 
The term “animal’ here denotes all mammalian animals 











Stages of development, including embryonic and fetal 
Stages. A “transgenic' animal is any animal containing cells 
that bear genetic information received, directly or indirectly, 
by deliberate genetic manipulation at the Subcellular level, 
Such as by microinjection or infection with recombinant 
WUS. 
“Transgenic’ in the present context does not encompass 
classical crossbreeding or in vitro fertilization, but rather 
denotes animals in which one or more cells receive a 
recombinant DNA molecule. Although it is highly preferred 
that this molecule be integrated within the animal's 
chromosomes, the invention also encompasses the use of 
extrachromosomally replicating DNA sequences, Such as 
might be engineered into yeast artificial chromosomes. 
The term “germ cell line transgenic animal' refers to a 
transgenic animal in which the genetic information has been 
taken up and incorporated into a germ line cell, therefore 
conferring the ability to transfer the information to offspring. 
If Such offspring, in fact, possess Some or all of that 
information, then they, too, are transgenic animals. 
The information to be introduced into the animal is 
preferably foreign to the Species of animal to which the 
recipient belongs (i.e., "heterologous'), but the information 
may also be foreign only to the particular individual 
recipient, or genetic information already possessed by the 
recipient. In the last case, the introduced gene may be 
differently expressed than is the native gene. 
The transgenic animals of this invention are other than 
human, and produce milk, blood Serum, and urine. Farm 
animals (pigs, goats, sheep, cows, horses, rabbits and the 
like), rodents (Such as mice), and domestic pets (for 
example, cats and dogs) are included in the Scope of this 
invention. 
It is highly preferred that a transgenic animal of the 
present invention be produced by introducing into Single cell 
embryos appropriate polynucleotides that encode human F8 
or v WF, or fragments or modified products thereof, in a 
manner Such that these polynucleotides are stably integrated 
into the DNA of germ line cells of the mature animal, and 
are inherited in normal mendelian fashion. 
Advances in technologies for embryo micromanipulation 
now permit introduction of heterologous DNA into fertilized 
mammalian ova. For instance, totipotent or pluripotent Stem 
cells can be transformed by microinjection, calcium phos 
phate mediated precipitation, lipoSome fusion, retroviral 
infection or other means, the transformed cells are then 
introduced into the embryo, and the embryo then develops 
into a transgenic animal. In a highly preferred method, 
developing embryos are infected with a retrovirus contain 
ing the desired DNA, and transgenic animals produced from 
the infected embryo. In a most preferred method, however, 
the appropriate DNAS are coinjected into the pronucleus or 
cytoplasm of embryos, preferably at the Single cell Stage, 
and the embryos allowed to develop into mature transgenic 
animals. Those techniques as well known. See reviews of 
Standard laboratory procedures for microinjection of heter 
ologous DNAS into mammalian fertilized ova, including 
Hogan et al., MANIPULATING THE MOUSE EMBRYO, 
(Cold Spring Harbor Press 1986); Krimpenfort et al., Bio/ 
Technology 9:844 (1991); Palmiter et al., Cell, 41: 343 
(1985); Kraemer et al., GENETIC MANIPULATION OF 
THE EARLY MAMMALIAN EMBRYO, (Cold Spring 
Harbor Laboratory Press 1985); Hammer et al., Nature, 315: 
680 (1985); Wagner et al., U.S. Pat. No. 5,175,385; 
Krimpenfort et al., U.S. Pat. No. 5,175,384, the respective 
contents of which are incorporated by reference. 
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Human F8 cDNA can be obtained by isolating it from an 
appropriate genomic Source (i.e., human liver which is the 
natural organ for production of this protein) by alternate 
methods which include preparation of cDNAs from isolated 
mRNA templates, direct Synthesis, or Some combination 
thereof, as described by Wood et al. 1984 above, and Toole 
et al. U.S. Pat. No. 4,757,006, which are incorporated by 
reference. 
The cDNAs encoding F8 or vWF or individual fragments 
or modified proteins thereof can be fused, in proper reading 
frame, with appropriate regulatory Signals as described in 
detail below, to produce a genetic construct that is then 
amplified, for example, by preparation in a bacterial (e.g., E. 
coli) plasmid vector, according to conventional methods. 
See Sambrook et al., Molecular Cloning. A Laboratory 
Manual (Cold Spring Harbor Press 1989), the contents of 
which are incorporated by reference. The amplified con 
struct is thereafter excised from the vector and purified for 
use in producing transgenic animals. Purification can be 
accomplished by means of one or more cycles of anionic 
HPLC, alternate techniques include ultracentrifugation 
through a Sucrose or NaCl gradient, gel electrolution fol 
lowed by agarose treatment and ethanol precipitation, or low 
preSSure chromatography. Purification by Several cycles of 
HPLC allows for remarkably high transformation 
frequencies, on the order of 20% or more in both mice and 
pigs. 
Although the present invention preferably entails the use 
of DNA constructs that produce the desired or native human 
F8 protein or VWF per se, the desired protein also may be 
produced as a fusion protein containing another protein. For 
example, the desired recombinant protein of this invention 
may be produced as part of a larger recombinant protein in 
order to Stabilize the desired protein or to make its purifi 
cation from milk faster and easier. The fusion partners then 
are Separated chemically or enzymatically, and the desired 
protein isolated. 
Recombinant human F8 (“rhF8”) may also be produced 
having the identical Sequence as the native molecule, or it 
may be produced as a fragment or derivative. A variety of 
modified rhE8 or subunits thereof can be produced by 
altering a cloned DNA using the well-known techniques of 
in vitro mutagenesis Such as those Set out in the references 
above. 
Production of transgenic animals containing the gene for 
rhF8 involves the use of cDNA or genomic DNA that 
encodes the precursor protein or heterodimeric rhE8. The 
full length base Sequence of each protein chain is disclosed 
in the aforementioned publication of Wood et al. and Toole 
et al., above. 
DNA constructs useful in the present invention provide a 
double stranded DNA sequence encoding rhE8 or rhvWF 
operably linked to all of the cis-acting Signals necessary for 
mammary gland-Specific expression of this protein, post 
translational glycosylation and Secretion of the protein into 
milk or other body fluids, and expression of full biological 
activity. 
Modified F8 or v WF DNA sequences also can be 
employed in this invention. Useful modifications within this 
context include, but are not limited to, those that alter 
post-translational modifications, size or active Site, or that 
fuse this protein or portions thereof to another protein. Such 
modifications can be introduced into the protein by tech 
niques well known in this art, Such as by Synthesizing 











introducing mutations into the cloned genes by, for example, 
oligonucleotide-mediated mutagenesis. 
The cis-acting regulatory regions useful in the invention 
include the promoter that drives expression of the F8 or 
Subunit chain genes. Highly preferred are promoters that are 
Specifically active in mammary gland cells and that involve 
milk proteins. Among Such promoters, highly preferred are 
the Short and long WAP, short and long C, B and kappa 
casein, C.-lactalbumin and B-lactoglobulin (“BLG”) promot 
CS. 
Promoters may be selected on the basis of the protein 
compositions of various milks. For example, the WAP and 
BLG promoters are particularly useful with transgenic 
rodents, pigs and sheep. The rodent WAP short and long 
promoters have been used to express the rat WAP gene, the 
human tPA gene and the CD4 gene, while the sheep BLG 
promoter has been used to express the sheep BLG gene, the 
human alpha-1-antitrypsin gene and the human Factor IX 
gene. For reviews see Paleyanda et al., 1991, above, and 
Clark et al., TIBTECH 5: 20 (1987), the respective content 
of which are incorporated herein by reference. Preferred 
among the promoters for carrying out the present invention 
are the rodent casein and WAP promoters, and the casein, 
C.-lactalbumin and BLG promoters from porcine, bovine, 
equine and Ovine (pigs, sheep, goats, cows, horses), rabbits, 
rodents and domestic pets (dogs and cats). The genes for 
these promoters have been isolated and their characteriza 
tions published. For reviews see Clark et al. (1987), above, 
and Henninghausen, Protein Expression and Purification4 
1: 3 (1990), the respective contents of which are incorpo 
rated herein by reference. 
The promoter may be isolated by carrying out conven 
tional restriction endonuclease and Subcloning Steps. A 
mouse WAP promoter, isolated as a 2.6 kb EcoR1-Kpn1 
fragment immediately 5' to the WAP Signal Sequence, is 
preferred, although the “long” WAP promoter (the 5' 4.2 kb 
Sau 3A-Kpn1 promoter of the mouse WAP gene, or a 
fragment thereof) is also Suitable for carrying out this 
invention. 
Important to the present invention are regulatory 
Sequences that direct Secretion of proteins into milk and/or 
other body fluids of the transgenic animal. In this regard, 
both homologous and heterologous regulatory Sequences are 
useful in the invention. Generally, regulatory Sequences 
known to direct the Secretion of milk proteins, Such as either 
Signal peptides from milk proteins or the nascent target 
polypeptide, can be used, although Signal Sequences can also 
be used in accordance with this invention that direct the 
Secretion of expressed proteins into other body fluids, par 
ticularly blood and urine. Most preferred for the transgenic 
mouse are the regulatory Sequences for the WAP protein. 
Among the useful Sequences that regulate transcription, in 
addition to the promoters discussed above, are enhancers, 
Splice Signals, transcription termination signals, and poly 
adenylation Sites. Particularly useful in this regard are those 
that increase the efficiency of the transcription of the genes 
for F8 or VWF in the mammary gland or other cells of the 
transgenic animals listed above. Preferred are transcription 
regulatory Sequences for proteins highly expressed in the 
mammary gland cells (see above). 
Preferably, the expression system or construct of this 
invention also includes a 3' untranslated region downstream 
of the DNA sequence encoding the desired recombinant 
protein, or the milk protein gene used for regulation. This 
region apparently Stabilizes the RNA transcript of the 
expression System and thus increases the yield of the desired 
5,880,327 
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protein. Among the 3' untranslated regions useful in this 
regard are Sequences that provide a poly A Signal. Such 
Sequences may be derived, e.g., from the SV 40 Small t 
antigen, the casein 3' untranslated region, or other 3' untrans 
lated sequences well known in this art. Preferably, the 3' 
untranslated region is derived from a milk-specific protein. 
Seq. ID No. 1 
Seq. ID No. 2 
The Stabilizing effect of this region's poly A transcript is 
important in stabilizing the mRNA of the expression 
Sequence. Also important in increasing the efficiency of 
expression of F8 are ribosome binding Sites. Likewise, 
Sequences that regulate the post-translational modification 
of F8 are useful in the invention. 
Thus, in accordance with this invention, a double 
Stranded chimeric DNA including genes encoding the F8 or 
VWF proteins or both, operably linked to cis-acting regula 
tory Sequences that promote efficient expression of the 
former in milk and/or other body fluids are introduced into 
an embryo where they are integrated into the embryonic 
genome and become part of the inheritable genetic endow 
ment of all of the animals cells, including the germline cells, 
of the adult that matures from the embryo. The recombinant 
proteins thus expressed and Secreted into milk are immu 
nologically reactive, as can be measured by an ELISA assay 
to be described below. 
Where the synthesis of a F8 subunit chain may be limiting 
in the production of the holoprotein, expression of this chain 
can be increased by placing the gene in a different genomic 
locus. This other locus can contain a DNA sequence under 
the same or a different regulatory Sequence than other 
Sequences. 
In a particularly preferred embodiment, the transgenes of 
the invention generally consist of WAP milk protein 
upstream and downstream flanking the F8 cDNA?signal 
peptide sequences (FIGS. 1 and 2). A native 5'-WAP regu 
latory Sequence ending in an accessible restriction site 
immediately before/at the ATG codon may be ligated to the 
restriction sites that occur at the ATG of translatable 
Sequences with no linker Sequences derived from the chains 
of human F8. Each of the combined 5'-regulatory and F8 
translatable Sequences ending in a particular restriction site 
may then be ligated to a corresponding restriction site which 
occurs at the beginning of the 3'-untranslated region of WAP 
and adjoining WAP 3'-flanking region. This construction 
motif enables native 5'-regulatory and 3'-UTR of the milk 
protein genes to be immediately juxtaposed without inter 
vening Sequences. Particular restriction Sites at the ends of 
all constructs may be selected in order to facilitate concat 
enation of constructs into a single domain within the animal 
genome. 
Although the above general descriptions of the DNA 
constructs of the invention have been given in terms of the 
WAP promoter, it is emphasized that other suitable promot 
ers (see above for discussion) may be ligated to the Factor 
VIII encoding polynucleotides in a similar manner. By way 
of illustration, the following discussion describes the use of 
the BLG promoter to increase the efficiency of expression of 
F8 and F8-BLG fusion proteins in mammary glands. 
8 
By means of techniques described above, F8-encoding 
cDNA can be inserted into an ovine BLG gene. For instance, 
in order to produce Such a construction, the 11.2 Kbp Ovine 
BLG gene may be modified to possess a unique EcoRV site 
upstream of the initiator ATG codon in the vector puCX 
SRV. The Sequence around this region is changed as follows: 
Pv Met Lys 
Natural CCCCAGCT GCAGCCAT GAAG 
EcoRV Met Lys 










This allows the cloning of blunt end fragments upstream 
of the BLG gene. The 7.5 kbp fragment from a plasmid (e.g., 
p122, FIG. 2) containing a CDNA encoding hF8 is isolated, 
blunt ends are generated with T4 DNA polymerase, and the 
product is ligated to EcoRV-cleaved puCXSRV. Following 
transformation of E. coli with this plasmid, clones that are 
produced can be characterized by restriction analysis of 
plasmid DNA prepared by a mini-prep method and by 
determination of the nucleotide Sequence around the 5' and 
3' cloning junctions for the DNA. Clones having the desired 
Structure can be used to produce transgenic rodents, pigs, 
sheep, cows, horses and other farm animals and domestic 
pets (cats and dogs) that Secrete a F8-BLG fusion product 
into their biological fluids as described below. 
A human F8 genomic Sequence also may be fused to the 
ovine BLG promoter illustrated in the following discussion. 
DNA sequences encoding ovine BLG in plasmid puCXSRV 
are deleted to generate a vector containing only Ovine BLG 
promoter sequences (pUCSV). As with puCSRV, blunt 
ended fragments may be fused to this promoter region by 
ligation to a unique EcoRV site. The Sequences 5' to this site 
are identical in both plasmids. 
Genomic F8 Sequences of greater than about 15 kbp can 
be introduced into transgenic animals, despite their length, 
through the use of cosmids with overlapping F8 Sequences, 
whereupon the necessary assembly of an entire genomic 
polynucleotide encoding hE8 is achieved by homologous 
recombination in Vivo after microinjection into an embryo 
cell. In constructs useful in the foregoing example, a plasmid 
in which the F8 genomic sequences are fused to ovine BLG 
3' flanking Sequences just after the F8 translation termination 
codon to ensure proper transcription, termination and poly 
adenylation. The hE8 gene fused to ovine BLG 3' flanking 
Sequences is excised from the plasmid, the 3' overhangs 
repaired using Klenow enzyme, and the product ligated to 
EcoRV-cleaved puCSR. Following transformation of E. 
coli, the resulting clones are characterized by restriction 
DNA analysis and by determining the nucleotide Sequences 
around the 5' and 3' cloning junctions. Clones having the 
desired Structure may be introduced into fertilized animal 
ova for production of transgenic animals. 
A variety of vectors based on the BLG gene may be 
constructed. In constructs based on this approach, the 
Sequences encoding the Ovine BLG protein are deleted, but 
the 5' promoter Sequences are retained. Each may possess a 
different complement of introns from the Ovine gene and a 
unique EcoRV site allowing the cloning of blunt ended 
fragments between the promoter and 3’ flanking region of 
the gene. However, each contains the BLG promoter, the 
EcoRV site and the BLG 3'-flanking sequence. For each 
recombinant, the 7.5 kbp KpnI fragment from p122 is 
isolated, blunt ends generated as above, and the product 
ligated to EcoRV-cleaved vector Sequences. Those con 
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Structs with the proper structures (determined as described 
above) may be used to express F8 in the biological fluids of 
transgenic animals. 
Doubly-transgenic mice which have native BLG genomic 
Sequences that are injected as Separate constructs to be 
concatenated in Vivo as additional flanking Sequences to the 
BLG target clDNA construct (such as, BLG promoter-Intron 
I-EcoRV-Intron VI-BLG 3' flank plus BLG) give higher 
expression more frequently than that observed with the use 
of constructs of the BLG promoter-F8 cDNA-BLG gene or 
BLG promoter-F8 genomic (tPLG 3' end). Intact or native 
BLG genomic Sequences that are preligated to the BLG 
cDNA target may give the same advantage. This same 
principle can be extended to WAP genomic Sequences. 
Obtaining milk from a transgenic animal according to the 
present invention is accomplished by conventional means. 
See, e.g., McBurney et al., J. Lab. Clin. Med. 64: 485 
(1964); Velander et al., Proc Natl. Acad. Sci. USA 89:12003 (1992), the respective contents of which are incorporated by 
reference. F8 or VWF or fragments thereof or protein prod 
ucts thereof can be isolated and purified from milk or urine 
by conventional means without deleteriously affecting activ 
ity. A preferred method consists of a combination of anion 
eXchange and immu no chromatographie S, 
cryoprecipitations, Zinc ion-induced precipitation of either 
whole milk or milk whey (defatted milk) proteins. For these 
techniques, see Bringe et al., J. Dairy Res. 56: 543 (1989), 
the contents of which are incorporated herein by reference. 
Milk is known to contain a number of proteases that have 
the potential to degrade foreign proteins. These include in 
the main an alkaline protease with tryptic and chymotryptic 
activities, a Serine protease, a chymotrypsin-like enzyme, an 
aminopeptidase and an acid protease. Clark et al. (1987) 
above. It may be desirable therefore to protect newly 
Secreted F8 or fragments thereof against proteolytic degra 
dation. Such precautions include rapid processing of the 
milk after collection and addition to the milk of well known 
inhibitors of proteolysis, such as are listed in SIGMA 
CHEMICAL CO. CATALOG (1993 edition) at page 850, 
the contents of which are incorporated herein by reference. 
As discussed above, under physiological conditions v WF 
complexes with circulating F8 and stabilizes the latter from 
degradation. In the present invention, the cDNA for v WF, 
which is available from the American Type Culture 
Collection, Rockville, Md. may be assembled into a con 
struct similar to that described in FIGS. 1 and 2 and 
microinjected into an embryo concurrently with the F8 
construct. Under such conditions, both proteins will be 
expressed and Secreted into the milk. 
For determination of newly secreted F8 and/or v Wif in 
milk whey, we have used the immunoradiometric assays 
essentially according to Hoyer et al., Methods Enzymol. 84: 
51,56-57 (1982), which is incorporated herein by reference. 
F8 antigens are measured with an radioiodinated human 
anti-F8 Fab' inhibitor antibody derived from patients with 
autoantibodies or transfused hemophiliac patients who have 
developed inhibitors. VWF antigens are measured with rab 
bit antibodies obtained by immunization with purified F8. 
Both assays use radiolabeled antibody that has been purified 
from immune complexes. Antigen measurement in these 
assays is based on the differential Solubility of the antigen 
antibody complexes and free antibody in ammonium Sulfate 
Solutions. 
The following examples are provided merely to illustrate 
the invention, and are not to be interpreted as limiting the 
Scope of the invention which is described in the Specification 












Construction of mWAP-hF8 cDNA Hybrid Gene 
A pPoly III-D vector (p120 in FIG. 2) was restricted with 
Kpn 1, blunt ended and religated to produce vector A 
without a Kpn 1 site. 
A 7.2 kb mWAP gene was excised from the p121 plasmid 
with Eco R1, blunted, and ligated into Vector A that was 
linearized with Eco R1. The product was a 9.3 kb plasmid 
(labeled p184) in which the WAP gene was flanked by Eco 
R1 and adjacent Not 1 restriction sites. 
Partial digestion of plasmid p122 with Kpn 1 produced a 
7.5 kb F8 cDNA flanked by Kpn 1 restriction sites. This 
cDNA was then inserted into plasmid p184 at a Kpn 1 site 
within the mWAP gene to produce plasmid p225.11, a 16.8 
kb plasmid. Flanking the human F8 gene is a 2.6 kb 5’mWAP 
segment with an upstream Not 1 site, and a 4.6 kb 3' mWAP 
gene with a downstream Not 1 site. 
As shown in FIG. 1, the 14.7 kb insert comprising the 5' 
mWAP/hF8/3' mWAP hybrid gene can be excised by Not 1 
digestion of the p225.11 plasmid, thereby releasing the 2.1 
kb pPoly III-D vector. 
The p225.11 plasmid has been deposited in the American 
Type Culture Collection, Rockville, Md. (ATCC Accession 
No. 97777). Applicants hereby provide assurances that: (1) 
during the pendency of this patent application access to the 
deposited plasmids will be made available to perSons prop 
erly designated by the Commissioner of Patents and Trade 
marks; (2) Subsequent to the issuance of this patent, the 
plasmids will be made available to the public without 
restriction for the enforceable life of the patent, or for five 
years after the last request for a sample, or for thirty years, 
whichever is longest; and, (3) nonviable plasmids will be 
replaced. 
EXAMPLE 2 
Assay for Factor VIII Protein in Milk Whey by an 
IRMA Assay 
The IRMA assay was used to estimate the concentration 
of recombinant human Factor VIII (recombinant human F8) 
in the milk whey of transgenic mice produced with the 
mWAP promoter system described above by the following 
procedure. 
Materials 
Whey, mouse f2.1.9.10 
Whey, mouse f2.13.9 
Whey, mouse f2.1.13.13 
Whey, mouse f2.1.22.8 
Whey, control mouse D15 
AS referenced above, an immunoradiometric assay 
(IRMA) was performed as described in Hoyer et al., Meth 
Ods in Enzymol. 84: 51-60 (1982). Iodinated anti-human 
Factor VIII Fab' fragments were used to detect recombinant 
Factor VIII in milk. 
Reagents 
Borate-buffered saline, pH 7.85 
Non-immune human IgG (Sigma) 
Heparin stock at 2000 U/ml, in borate saline buffer 
Normal pooled plasma (NPP) 






1) Heparin was diluted to 4 U/ml in 2% non-immune 
human IgG as a carrier protein in buffer. 
2) A standard curve with serial dilutions of NPP (1:2 to 
1:128) was set up, with buffer as the blank. All stan 
dards and Samples were assayed in duplicate. 
3) To 12x75 mm polystyrene tubes were added the 
following: 
50 it 2% non-immune human IgG 
50 uL NPP buffer or test milk whey samples 
50 uAL of 'I-labeled Fab' fragments (about 1000 
cpm) 
4) Tubes were vortexed and incubated in a 37° C. water 
bath for 2 hours, to allow complex formation between 
Fab' and Factor VIII antigen. 
5) 200 uL of a 95% solution of ammonium sulfate was 
added and incubated at room temperature for 30 min 
uteS. 
6) The tubes were centrifuged at 2,800 rpm at room 
temperature for 30 minutes. The pellet was washed 
twice with 1 mL of a 38% ammonium Sulfate Solution 
and recentrifuged as above for 20 minutes. 
7) The Supernatant was decanted and the pellets assayed 
for residual radioactivity in a gamma-counter. ASSay 
values were determined by reference to the Standard 
CWC. 
The results of IRMA tests are shown in the table below. 
Factor VIII 
PDL Designation Sample vol.* antigen 
Mouse ID no. ful units/ml ng/ml 
Control D15 1OO O.O41 8.2 
F2.1.13.9 1OO O.O45 9.O 
F2.1.9.10 50 O.1OO 2O.O 
F2.1.22.8 40 0.144 28.8 
F2.1.13.13 50 O.O93 18.6 
*Samples stored at -20°C. In 2 animals, storage of the milk at 4 C. led to 
reduced values a recombinant human FV III. 
Relative to the background value for this method (control 
mouse D15), antigen (F8) production was elevated on an 
average of about 250% in three of four mice. 
EXAMPLE 3 
Western Blots of Mouse Whey Samples 
Milk wheys from two transgenic mice (F2 and F3) were 
immunoblotted in order to identify recombinant human 
Factor VIII (recombinant human F8) in the samples. Western 
blots are shown in FIG. 3. 
Thrombin Buffer: 0.15M NaCl, 20 mM M HEPES, 5 mM 









Thrombin: 2 units/mL 
TBS: 20 mM Tris, 500 mM NaCl, pH 8.0 
TBS/T TBS with 0.05% Tween 20 
TBS/T/NFDM TBS/T with 5% Non-fat dry milk 
Primary antibody in 1x TBS/T/NFDM: 
Monoclonal antibody 413 (2 tug/ml; anti-heavy chain) 
Monoclonal antibody 37 (5ug/ml; anti-light chain) 
Secondary antibody diluted 1:6000 in 1x TBS/T 
Streptavidin, alkaline phosphatase conjugate (GIBCO) 
LumiPhoS Luminescent Biotin-conjugated Development 
System (Boerhringer-Mannheim) 
Procedure 
1) Whey samples (200 ug total protein) were digested 
with thrombin (130 uU?ul ) for 5 minutes. An equal 
volume of 2x Sample Buffer was added and samples 
were boiled for 5 minutes, and quickly cooled on ice. 
2) Samples were run on 1.2 mm-thick 7.5% acrylamide 
Laemmli gel. Proteins were electroblotted onto nitro 
cellulose membrane at 12 volts for 1.5 hours. The 
membrane was stored in TBS at 4 C. 
3) The membrane was blocked in TBS/T/NFDM for 1 
hour and washed 3 times in TBS/T. 
4) Primary antibody was added to the membrane for 2 
hours at 25 C., then washed 3 times in TBS/T. 
5) The membrane was incubated in secondary antibody 
for 15 minutes at 25°C., then washed 4 times in TBS/T. 
6) The membrane was incubated in LumiPhos according 
to manufacturer's directions for 20 minutes in the dark. 
7) The membrane was exposed to Kodak XAR-5 film for 
25 minutes. The film was developed in a Kodak pro 
CCSSO. 
The first lane on the left consists of molecular weight 
markers from 45 to 200 kDa. The second from the left lane 
is standard hE8 showing a major band at about 80 kDa and 
another at about 210 kDa. The third lane from the left shows 
control whey proteins. The F2 and F3 lanes show transgenic 
milk wheys, there were Strongly staining new bands at about 
80 kDa, compared to the control, in parallel to the Standard 
hF8. The F2 and F3 lanes also show intensely staining bands 
at about 120 kDa, a band that is relatively faint in the control 
and apparently absent from standard hE8. Its identity is 
unknown. 
Taken together, the data of Examples 2 and 3 demonstrate 
that the transgenic mice of the invention expressed authentic 
recombinant human F8 and secreted this protein into the 
animal's milk. 
SEQUENCE LISTING 
( 1) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 2 
( 2) INFORMATION FOR SEQ ID NO:1: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 20 base pairs 




(D) TOPOLOGY: linear 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
C C C C A G C T G C A G C CAT GAA G 2 O 
( 2) INFORMATION FOR SEQ ID NO:2: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 28 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
C C C CA. GGG AT A T C C C T G CAG C CAT GAA G 28 
2O We claim: 
1. A non-human transgenic mammal that produces in its 
mammary gland cells and Secretes into its milk at detectable 
levels a recombinant human Factor VIII protein or fragment 
or modification thereof having physiological activity of 
human Factor VIII, wherein Said transgenic mammal has 
Stably integrated into its genome an exogenous gene con 
Struct comprising: 
(A) 5’ expression regulating sequences, including a mam 
mary gland-Specific promoter; 
(B) DNA encoding said Factor VIII protein or fragment or 
modification thereof, and a Signal Sequence effective in 
directing Secretion of Said Factor VIII protein or frag 
ment thereof into the milk of Said transgenic mammal; 
and 
(C) 3' regulatory sequences, including a polyadenylation 
Signal, that result in the expression of Said DNA in Said 
mammary gland cells, 
wherein (A), (B), and (C) are operably linked in Said gene 
construct to obtain production of said Factor VIII protein or 
fragment or modification thereof in Said mammary gland 
cells and Secretion thereof into the milk of Said transgenic 
mammal. 
2. The non-human transgenic mammal according to claim 
1, wherein Said promoter is a milk protein gene promoter. 
3. The non-human transgenic mammal according to claim 
2, wherein Said milk protein gene promoter is Selected from 
the group consisting of whey acidic protein, casein, lactal 
bumin and beta-lactoglobulin promoters. 
4. The non-human transgenic mammal according to claim 
1, wherein said human Factor VIII protein or fragment 
thereof is a single chain protein or a multimeric protein. 
5. The non-human transgenic mammal according to claim 
4, wherein said human Factor VIII protein or fragment 
thereof is a single chain protein or a heterodimeric protein 
composed of a C-terminal light chain of human Factor VIII 
and an N-terminal heavy chain of human Factor VIII. 
6. The non-human transgenic mammal according to claim 
5, wherein Said C-terminal light chain has a molecular 
weight of about 80 kDa and said N-terminal heavy chain of 
human Factor VIII has a molecular weight of about 210 kDa. 
7. The non-human transgenic mammal according to claim 
1, wherein Said transgenic mammal produces human Factor 
VIII protein. 
8. The non-human transgenic mammal according to claim 
7, wherein said human Factor VIII protein has the amino 









9. The non-human transgenic mammal according to claim 
1, wherein Said 3' regulatory Sequences are 3' untranslated 
regions from a milk protein gene or from a human Factor 
VIII gene. 
10. The non-human transgenic mammal according to 
claim 1, wherein Said transgenic mammal is Selected from 
the group consisting of mouse, rat, rabbit, pig, sheep, goat 
and cattle. 
11. The non-human transgenic mammal according to 
claim 1, wherein Said mammal is female. 
12. A proceSS for producing recombinant human Factor 
VIII protein or fragment thereof having physiological activ 
ity of human Factor VIII, comprising the steps of: 
(a) providing a non-human transgenic mammal having 
integrated into its genome a an exogenous gene con 
Struct comprising: (A) 5’ expression regulating sequences, including a 
mammary gland-specific promoter; 
(B) DNA encoding said Factor VIII protein or fragment 
thereof, and a Signal Sequence effective in directing 
secretion of said Factor VIII protein or fragment 
thereof into the milk of Said transgenic mammal; and (C) 3' regulatory Sequences, including a polyadenyla 
tion signal, that result in the expression of Said DNA 
Sequences in mammary gland cells of Said transgenic 
animal, 
wherein (A), (B), and (C) are operably linked in Said gene 
construct to obtain production of said Factor VIII protein or 
fragment thereof in Said mammary gland cells and Secretion 
thereof into the milk of Said transgenic mammal, 
(b) allowing said DNA encoding said Factor VIII protein 
or fragment thereof to be expressed and Said Factor 
VIII or fragment thereof to be secreted into the milk of 
Said transgenic mammal, 
(c) collecting milk from Said mammal, and, 
(d) isolating said Factor VIII protein or fragment thereof 
from said milk. 
13. The process according to claim 12, wherein Said 
mammal is induced to lactate prior to Said collecting Step. 
14. The process according to claim 12, wherein Said 
promoter is a milk protein gene promoter. 
15. The process according to claim 14, wherein said milk 
protein gene promoter is Selected from the group consisting 
of whey acidic protein, casein, lactalbumin and beta 
lactoglobulin promoters. 
16. The process according to claim 12, wherein Said 
human Factor VIII protein or fragment or modification 
thereof is a Single chain protein or a multimeric protein. 
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17. The process according to claim 16, wherein Said 
human Factor VIII protein or fragment thereof is a Single 
chain protein or a heterodimeric protein composed of a 
C-terminal light chain of human Factor VIII and an 
N-terminal heavy chain of human Factor VIII. 
18. The process according to claim 17, wherein said 
C-terminal light chain has a molecular weight of about 80 
kDa and said N-terminal heavy chain of human Factor VIII 
has a molecular weight of about 210 kDa. 
19. The process according to claim 12, wherein Said 
transgenic mammal produces human Factor VIII protein. 
20. The process according to claim 19, wherein said 
human Factor VIII protein has the amino acid Sequence of 
human Factor VIII. 
21. The process according to claim 12, wherein Said 3' 
regulatory Sequences are 3' untranslated regions from a milk 
protein gene or from a human Factor VIII gene. 
22. The process according to claim 12, wherein Said 
transgenic mammal is Selected from the group consisting of 
mouse, rat, rabbit, pig, sheep, goat and cattle. 
23. The process according to claim 12, wherein Said 
mammal is female. 
24. A process for producing a non-human transgenic 
mammal that produces in its mammary gland cells and 
Secretes into its milk a human Factor VIII protein or frag 
ment thereof having physiological activity of human Factor 
VIII, comprising the Steps of: 
(a) providing an exogenous gene construct comprising: 
(A) 5’ expression regulating sequences, including a 
mammary gland-specific promoter; 
(B) DNA encoding said Factor VIII protein or fragment 
thereof, and a Signal Sequence effective in directing 
Secretion of said Factor VIII protein or fragment 
thereof into the milk of Said transgenic mammal, and (C) 3' regulatory sequences, including a polyadenyla 
tion signal, that result in the expression of Said DNA 
in the milk of Said transgenic mammal, 
wherein (A), (B), and (C) are operably linked in Said gene 
construct to obtain production of said Factor VIII protein or 
fragment thereof in Said mammary gland cells and Secretion 
thereof into the milk of Said transgenic mammal; 
b) introducing the construct of Step (a) into a non-human 
mammalian embryo, wherein Said construct is stably 
integrated into the genome of Said mammalian embryo, 
(c) permitting Said embryo to develop into a non-human 
transgenic mammal; and 
(d) determining that the non-human transgenic mammal 
of (c) produces said Factor VIII protein or fragment 
thereof. 
25. The process according to claim 24, wherein Said 
construct of step (a) is in the form of DNA, DNA in a vector, 
DNA contained in one or more organelles or other parts of 
a cell or DNA contained in one or more whole cells. 
26. The process according to claim 24, wherein Said 








27. The proceSS according to claim 26, wherein Said milk 
protein gene promoter is Selected from the group consisting 
of whey acidic protein, casein, lactalbumin and beta 
lactoglobulin promoters. 
28. The process according to claim 24, wherein Said 
human Factor VIII protein or fragment thereof is a Single 
chain protein or a multimeric protein. 
29. The process according to claim 28, wherein said 
human Factor VIII protein or fragment thereof comprises a 
Single chain protein or a heterodimeric protein composed of 
a C-terminal light chain of human Factor VIII and an 
N-terminal heavy chain of human Factor VIII. 
30. The process according to claim 29, wherein said 
C-terminal light chain has a molecular weight of about 80 
kDa and said N-terminal heavy chain of human Factor VIII 
has a molecular weight of about 210 kDa. 
31. The process according to claim 24, wherein Said 
transgenic mammal produces human Factor VIII protein. 
32. The process according to claim 31, wherein Said 
human Factor VIII protein has the amino acid Sequence of 
human Factor VIII. 
33. The process according to claim 24, wherein said 3' 
regulatory Sequences are 3' untranslated regions from a milk 
protein gene or from a human Factor VIII gene. 
34. The process according to claim 24, wherein Said 
transgenic mammal is Selected from the group consisting of 
mouse, rat, rabbit, pig, sheep, goat and cattle. 
35. The process according to claim 24, wherein Said 
mammal is female. 
36. The process according to claim 24, wherein Said 
mammal is male. 
37. The process according to claim 12 or 24, wherein said 
exogenous gene construct is contained in plasmid p225.11 
(ATCC Accession No. 9777). 
38. The non-human transgenic mammal according to 
claim 1 wherein Said exogenous gene construct comprises 
the mouse WAP promoter and gene, and the 3'regulatory 
sequence of the WAP gene, wherein human Factor VIII 
cDNA is inserted into the Kpn site of the WAP gene. 
39. The non-human mammal according to claim 1, 
wherein Said exogenous gene construct is contained in 
plasmid p225.11 (ATCC Accession No. 9777). 
40. The process according to claim 12 or 24, wherein said 
exogenous gene construct comprises the mouse WAP pro 
moter and gene, and the 3' regulatory Sequence of the WAP 
gene, wherein human Factor VIII cDNA is inserted into the 
Kpn site of the WAP gene. 
41. Cells obtained from the non-human transgenic mam 
mal of claim 1, wherein Said cells have stably integrated into 
their genome Said exogenous gene construct. 
42. The cells according to claim 41, wherein Said cells 
produce said recombinant human Factor VIII protein or 
fragments thereof. 
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